SCHEMBL10229795

SCHEMBL10229795

CS(=O)(=O)c1ccc(Cc2nnc(SCc3ccc(F)cc3Cl)n2-c2ccc(F)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.51
GPBAR1 Q8TDU6 1/20 0.47
NPSR1 Q6W5P4 3/20 0.46
HTT P42858 1/20 0.46
RECQL P46063 1/20 0.46
TP53 P04637 4/20 0.44
MAPT P10636 4/20 0.44
RAB9A P51151 2/20 0.44
KDM4E B2RXH2 1/20 0.44
PTGS2 P35354 3/20 0.42
PTGS1 P23219 1/20 0.42
HSD17B10 Q99714 2/20 0.42
ALDH1A1 P00352 3/20 0.42
TSHR P16473 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.40
MAPK1 P28482 1/20 0.40
NPC1 O15118 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10229764 0.85 SMN1; SMN2 (0.71) SMN1; SMN2GPBAR1NPSR1HTTRECQL
SCHEMBL10229742 0.85 TP53 (0.58) SMN1; SMN2GPBAR1NPSR1HTTRECQL
SCHEMBL10229731 0.84 GPBAR1 (0.51) SMN1; SMN2GPBAR1NPSR1HTTRECQL
SCHEMBL10229757 0.84 SMN1; SMN2 (0.54) SMN1; SMN2GPBAR1NPSR1HTTRECQL
SCHEMBL10229660 0.83 SMN1; SMN2 (0.48) SMN1; SMN2GPBAR1NPSR1HTTRECQL
SCHEMBL13259981 0.83 SMN1; SMN2 (0.58) SMN1; SMN2GPBAR1NPSR1HTTRECQL
SCHEMBL13259963 0.82 GPBAR1 (0.48) SMN1; SMN2GPBAR1NPSR1HTTRECQL
SCHEMBL10229785 0.81 GPBAR1 (0.70) SMN1; SMN2GPBAR1NPSR1HTTRECQL
SCHEMBL10229629 0.80 GPBAR1 (0.64) SMN1; SMN2GPBAR1NPSR1HTTRECQL
SCHEMBL10229673 0.79 HTT (0.48) SMN1; SMN2GPBAR1NPSR1HTTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785488-B2 Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity EXELIXIS PATENT COMPANY LLC (US) 2014-07-22 US disclosed
US-8785488-B2 Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity EXELIXIS PATENT COMPANY LLC (US) 2014-07-22 US disclosed
US-20120040985-A1 TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY EXELIXIS PATENT COMPANY LLC (US) 2012-02-16 US disclosed
US-20120040985-A1 TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY EXELIXIS PATENT COMPANY LLC (US) 2012-02-16 US disclosed
WO-2010093845-A1 TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY EXELIXIS, INC. (US) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040985-A1 TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY GPR119, GLP1R, GCGR SMN1; SMN2 4789/4885GPBAR1 8/4885NPSR1 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.